The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Table 3 Arm B (vaccine + GM-CSF): patient profiles, clinical data, and immunological outcomes

Pt	Age	Cancer	Stage on enrollment	# of cycles	Off-study reason	PFS^#(ms)	OS* (ms)	Immune response
Pt	Age	Cancer	Stage on enrollment	# of cycles	Off-study reason	PFS^#(ms)	OS* (ms)	Proliferative assay		Elispot
								Pre-vaccine	Post-vaccine	Pre-vaccine	Post-vaccine
1B	55	Biliary	NED	3	PD	2.9	8.7	+	+	+	+
2B	33	Colon	IV	3	PD	2.9	16.9	-	+	NA
3B	51	Colon	IV	5	PPS/Lost to follow-up	9.2+	52.6	+	+	-	+
4B	48	Pancreatic	NED	13	Completed	35.4+	35.4	-	+	-	-
5B	51	Colon	IV	1	PD	1	1.5	ND
6B	38	Colon	IV	1	Refused further Tx	0.2+	8.3	ND
7B	60	Pancreatic	IV	3	PD	4.6	21	-	-	NA
8B	57	Colon	IV	3	PD	3.1	6.8	NA
9B	52	Colon	IV	3	PD	3.3	28.3	-	+	+	+
10B	58	Pancreatic	IV	3	PD	2.9	20.9	+	+	-	+
11B	45	Pancreatic	IV	2	PD	1	7.3	ND
12B	79	Colon	IV	3	PPS	12.9	42.1	-	+	-	+
13B	43	Colon	IV	3	PD	2.6	6.3	-	-	-	+
14B	78	Colon	NED	8	Left voluntarily	16.8	69	-	+	-	+
15B	63	Colon	IV	3	PD	2.8	11.6	+	+	-	+
16B	64	Colon	IV	6	PD	5.7	20.7	-	+	-	-
17B	71	Colon	IV	6	PD	5.6	25.9	-	+	-	+
18B	58	Pancreatic	IV	2	PD	2.6	3.3	ND

^#Progression free survival was calculated as time from the date the consent was signed until evidence of disease progression or last follow-up without progression (+). *Overall Survival was calculated as time from consent date until death or last follow-up (+). ND, not done because patient received 2 or less vaccines; NA, sample not available. Arm B (Vaccine + GM-CSF): Patient Profiles, Clinical Data, and Immunological Outcomes.
Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall Survival, ms Months.